The virus found a way around one layer of defense
En los primeros días de septiembre de 2021, Perú se encontraba ante un umbral familiar: el de un virus que muta, se desplaza y desafía las defensas construidas con esfuerzo. El Instituto Nacional de Salud confirmó 67 casos de la variante Mu del COVID-19 en 13 regiones del país, una cepa originada en Colombia que porta mutaciones capaces de evadir parcialmente la inmunidad adquirida por vacunación o infección previa. Aunque su prevalencia global era aún marginal, la historia reciente de países vecinos recordaba que los números pequeños no siempre permanecen pequeños.
- La variante Mu, detectada por primera vez en Perú en mayo en un paciente de Moquegua, ya se había extendido a 13 regiones —incluyendo Lima, Arequipa y Tacna— en un patrón de dispersión que sugería múltiples focos simultáneos, no un brote aislado.
- Sus mutaciones en la proteína spike encendieron las alarmas: la variante podría infectar a personas ya vacunadas o con inmunidad natural, una capacidad de escape inmune que la OMS consideró suficiente para clasificarla como variante de interés.
- Diez pacientes vacunados en Perú contrajeron COVID-19 por la variante Mu, demostrando que la protección de las vacunas no era absoluta frente a esta cepa, aunque ninguno desarrolló enfermedad grave.
- En Colombia, país de origen de la variante, Mu representaba el 39% de los casos; en Ecuador, el 13%; en Perú, los números eran aún bajos, pero la trayectoria regional advertía que la vigilancia no podía relajarse.
- Las autoridades sanitarias peruanas anticipaban una tercera ola en los próximos meses, con la variante Mu como uno de sus posibles motores, en un país que ya había soportado dos oleadas devastadoras.
A comienzos de septiembre de 2021, el Instituto Nacional de Salud del Perú confirmó 67 casos de la variante Mu del COVID-19 distribuidos en 13 regiones del país. La variante no era desconocida en la región: había surgido en Colombia en enero de ese año y desde allí había avanzado hacia Ecuador y luego hacia Perú. El primer caso peruano se registró en mayo, en un paciente de Moquegua, en el sur andino del país.
Lo que preocupaba de la variante Mu no era su prevalencia —apenas el 0,1% de los casos globales— sino su arquitectura genética. Las mutaciones en su proteína spike sugerían una capacidad de escape inmune: la posibilidad de infectar a personas que ya habían sido vacunadas o que habían superado una infección previa. La OMS la había clasificado como variante de interés, una señal de alerta que no podía ignorarse.
Lely Solari, especialista en enfermedades infecciosas del Instituto Nacional de Salud, confirmó que diez pacientes vacunados en Perú habían contraído COVID-19 por esta variante. Sin embargo, subrayó un matiz crucial: ninguno había desarrollado enfermedad grave. Las vacunas no habían impedido la infección, pero sí habían cumplido su función más importante: evitar los peores desenlaces.
El contexto regional añadía urgencia al panorama. En Colombia, la variante Mu representaba el 39% de los contagios; en Ecuador, el 13%. Perú observaba esa trayectoria con cautela. El Ministerio de Salud ya anticipaba una posible tercera ola en los meses siguientes, y la variante Mu era una de las razones para esperarla. Un país que había atravesado dos olas devastadoras sabía bien que los números pequeños podían crecer, y que el virus seguía evolucionando sin pedir permiso.
By early September 2021, Peru's National Health Institute had confirmed something that health officials had been tracking with growing concern: sixty-seven cases of the Mu variant of COVID-19, scattered across thirteen regions of the country. The variant itself was not new to the Americas—it had first appeared in Colombia months earlier, in January, and had since moved into Ecuador and now into Peru. But its presence in Peru marked another threshold crossed, another reason to watch the horizon for what might come next.
The first Peruvian case had surfaced in May, in a patient from Moquegua, a region in the southern highlands. From there, the variant had spread. By the time Lely Solari, an infectious disease specialist at the National Health Institute, spoke to reporters, cases had been documented in Tacna, Arequipa, Lima, Callao, and across more than a dozen other departments. The geographic scatter suggested the variant was not confined to a single outbreak but was moving through the country's population in multiple places at once.
What made the Mu variant worth the attention was not its current prevalence—globally, it accounted for only about 0.1 percent of COVID cases—but rather what it carried in its genetic structure. The variant possessed mutations in its spike protein, the part of the virus that allows it to enter human cells and that vaccines train the immune system to recognize. Those mutations raised a specific concern: immune escape. In plain terms, this meant the variant might be able to infect people who had already been exposed to the virus through natural infection or vaccination. The World Health Organization had classified Mu as a variant of interest, a category reserved for mutations that warranted close monitoring.
In neighboring Colombia, where the variant had originated, it accounted for thirty-nine percent of all COVID cases. In Ecuador, thirteen percent. Both countries had seen the variant's share of infections climbing steadily. Peru's numbers were still small, but the trajectory elsewhere suggested vigilance was warranted.
Solari noted that ten vaccinated patients in Peru had contracted COVID-19 from the Mu variant. This was not insignificant—it demonstrated that vaccination did not provide complete protection against this particular mutation. However, she was careful to add an important qualifier: none of those ten had developed severe illness. They had been infected, but the vaccines had still done their primary job of preventing the worst outcomes. The distinction mattered. A variant that could evade immunity but still left vaccinated people with mild or moderate disease was a different threat than one that left them hospitalized.
The broader context was one of uncertainty and preparation. Peru had endured a devastating first and second wave of COVID-19. The Ministry of Health was already anticipating a third wave in the coming months. The Mu variant was one reason to expect it, though not the only one. As vaccination campaigns continued and people moved about the country, the virus found new opportunities to spread. Whether Mu would become the dominant variant in Peru, as it had in Colombia, remained to be seen. What was clear was that the pandemic was not finished with Peru, and the virus continued to evolve in ways that demanded attention.
Notable Quotes
This variant has mutations that suggest immune escape—people already exposed through infection or vaccination can still become infected— Lely Solari, infectious disease specialist, National Health Institute
We reported the first case in May in a patient from Moquegua, and to date we have 67 identified cases across 13 regions and Callao— Lely Solari, National Health Institute
The Hearth Conversation Another angle on the story
Why does a variant that represents only 0.1 percent of global cases warrant this level of concern?
Because prevalence isn't the whole story. In Colombia and Ecuador, it's already thirty-nine and thirteen percent respectively. We're watching a variant that's spreading faster in the places where it's already taken hold. Peru is seeing what those countries saw a few months ago.
The fact that vaccinated people got infected—does that mean the vaccines failed?
No. Ten vaccinated people got infected, but none got severely ill. That's the distinction that matters. The vaccine still protected them from the worst. Immune escape doesn't mean the vaccine is useless; it means the virus found a way around one layer of defense.
If it's in thirteen regions already, how did it spread so quickly?
We don't know exactly. It could be more transmissible than other variants—the spike protein mutations suggest that's possible. Or it could be epidemiological chance. Either way, once it's in multiple regions, it moves with people. Trade, travel, daily life.
What happens next?
The Ministry expects a third wave. Whether Mu becomes the dominant variant here like it did in Colombia, or whether other variants take over, the pressure on the health system will likely increase. That's why they're tracking it so carefully now.
Should people be alarmed?
Concerned, yes. Alarmed, no. The vaccinated people who got infected didn't get severely ill. The variant is being monitored. But this is a reminder that the pandemic isn't over, and the virus keeps changing.